Inovio
INO
performed incredibly well last week due do a $71 grant from the DoD and pending Phase 1 results of INO-4800 which were said to be realeased late June.
Expect a dip, before rising to analysts target of $45.
Fundemental Analysis
1. Dr Fauci announced yesterday evening that positive vaccine results were to be released over the next few days.
2. China and South Korea implementation of Phase 1 which will be funded by CEPI.
3. S. Korea, BARDA and DARPA funding to come.
4. Likely approval from FDA to go onto phase 3 trials when results are confirmed to be positive.
Technical Analysis
1. Volume picking up massively this last week, as RobinHood traders continue to get on board.
2. RSI fallen towards 50 after Fridays slight fall in stock price, giving the stock a chance for another sudden rise in prices.
3. Strong support levels around 27.55 and 23.51
INO
performed incredibly well last week due do a $71 grant from the DoD and pending Phase 1 results of INO-4800 which were said to be realeased late June. Expect a dip, before rising to analysts target of $45.
Fundemental Analysis
1. Dr Fauci announced yesterday evening that positive vaccine results were to be released over the next few days.
2. China and South Korea implementation of Phase 1 which will be funded by CEPI.
3. S. Korea, BARDA and DARPA funding to come.
4. Likely approval from FDA to go onto phase 3 trials when results are confirmed to be positive.
Technical Analysis
1. Volume picking up massively this last week, as RobinHood traders continue to get on board.
2. RSI fallen towards 50 after Fridays slight fall in stock price, giving the stock a chance for another sudden rise in prices.
3. Strong support levels around 27.55 and 23.51